Epistem, Biosurfit Developing HCV Assays as Part of €6M EC Consortium | GenomeWeb

NEW YORK (GenomeWeb News) – UK biotech firm Epistem said today that it has received €1.5 million ($2 million) from the European Commission to develop point-of-care diagnostic tests for Hepatitis C as part of a €6 million, international project called the PoC HCV consortium.

The consortium aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.